168 related articles for article (PubMed ID: 16652121)
1. Myofibroblastic stromal reaction and expression of tenascin-C and laminin in prostate adenocarcinoma.
Tomas D; Ulamec M; Hudolin T; Bulimbasić S; Belicza M; Kruslin B
Prostate Cancer Prostatic Dis; 2006; 9(4):414-9. PubMed ID: 16652121
[TBL] [Abstract][Full Text] [Related]
2. The potential value of (Myo)fibroblastic stromal reaction in the diagnosis of prostatic adenocarcinoma.
Tomas D; Kruslin B
Prostate; 2004 Dec; 61(4):324-31. PubMed ID: 15389817
[TBL] [Abstract][Full Text] [Related]
3. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling.
Tuxhorn JA; Ayala GE; Smith MJ; Smith VC; Dang TD; Rowley DR
Clin Cancer Res; 2002 Sep; 8(9):2912-23. PubMed ID: 12231536
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic characterization of human prostatic stromal cells in primary cultures derived from human tissue samples.
Gravina GL; Mancini A; Ranieri G; Di Pasquale B; Marampon F; Di Clemente L; Ricevuto E; Festuccia C
Int J Oncol; 2013 Jun; 42(6):2116-22. PubMed ID: 23589051
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of normal stromal components and their correlation with cancer occurrence in human prostate.
Zhang Y; Nojima S; Nakayama H; Jin Y; Enza H
Oncol Rep; 2003; 10(1):207-11. PubMed ID: 12469170
[TBL] [Abstract][Full Text] [Related]
6. mRNA expression and protein distribution of the unspliced tenascin-C isoform in prostatic adenocarcinoma.
Katenkamp K; Berndt A; Hindermann W; Wunderlich H; Haas KM; Borsi L; Zardi L; Kosmehl H
J Pathol; 2004 Jul; 203(3):771-9. PubMed ID: 15221936
[TBL] [Abstract][Full Text] [Related]
7. Molecular characterization of the desmoplastic tumor stroma in medullary thyroid carcinoma.
Koperek O; Scheuba C; Puri C; Birner P; Haslinger C; Rettig W; Niederle B; Kaserer K; Garin Chesa P
Int J Oncol; 2007 Jul; 31(1):59-67. PubMed ID: 17549405
[TBL] [Abstract][Full Text] [Related]
8. [Phenotypic differences of stroma cells in benign and malignant human prostate tissues].
Zhou H; Sun HB; Huang WB; Xu Z; Su JH; Zhu JG; Jia RP; Liu J
Zhonghua Yi Xue Za Zhi; 2012 Feb; 92(8):516-9. PubMed ID: 22490152
[TBL] [Abstract][Full Text] [Related]
9. Intensity of stromal changes predicts biochemical recurrence-free survival in prostatic carcinoma.
Tomas D; Spajić B; Milosević M; Demirović A; Marusić Z; Kruslin B
Scand J Urol Nephrol; 2010 Nov; 44(5):284-90. PubMed ID: 20459359
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of galectin-1 in carcinoma-associated stroma predicts poor outcome in prostate carcinoma patients.
van den Brûle FA; Waltregny D; Castronovo V
J Pathol; 2001 Jan; 193(1):80-7. PubMed ID: 11169519
[TBL] [Abstract][Full Text] [Related]
11. Role of stromal tenascin-C in mouse prostatic development and epithelial cell differentiation.
Ishii K; Imanaka-Yoshida K; Yoshida T; Sugimura Y
Dev Biol; 2008 Dec; 324(2):310-9. PubMed ID: 18950615
[TBL] [Abstract][Full Text] [Related]
12. IL-6, IL-10 and HSP-90 expression in tissue microarrays from human prostate cancer assessed by computer-assisted image analysis.
Cardillo MR; Ippoliti F
Anticancer Res; 2006; 26(5A):3409-16. PubMed ID: 17094460
[TBL] [Abstract][Full Text] [Related]
13. Abnormal G-actin content in single prostate cells as a biomarker of prostate cancer.
Hemstreet GP; Bonner RB; Hurst RE; Bell D; Bane BL
Cancer Detect Prev; 2000; 24(5):464-72. PubMed ID: 11129989
[TBL] [Abstract][Full Text] [Related]
14. Comparative expression of Hedgehog ligands at different stages of prostate carcinoma progression.
Azoulay S; Terry S; Chimingqi M; Sirab N; Faucon H; Gil Diez de Medina S; Moutereau S; Maillé P; Soyeux P; Abbou C; Salomon L; Vacherot F; de La Taille A; Loric S; Allory Y
J Pathol; 2008 Dec; 216(4):460-70. PubMed ID: 18825689
[TBL] [Abstract][Full Text] [Related]
15. Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer.
Ayala G; Tuxhorn JA; Wheeler TM; Frolov A; Scardino PT; Ohori M; Wheeler M; Spitler J; Rowley DR
Clin Cancer Res; 2003 Oct; 9(13):4792-801. PubMed ID: 14581350
[TBL] [Abstract][Full Text] [Related]
16. Tenascin expression in cancer cells and stroma of human breast cancer and its prognostic significance.
Ishihara A; Yoshida T; Tamaki H; Sakakura T
Clin Cancer Res; 1995 Sep; 1(9):1035-41. PubMed ID: 9816077
[TBL] [Abstract][Full Text] [Related]
17. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K
Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661
[TBL] [Abstract][Full Text] [Related]
18. Claudin expression is dysregulated in prostate adenocarcinomas but does not correlate with main clinicopathological parameters.
Coutinho-Camillo CM; Lourenço SV; da Fonseca FP; Soares FA
Pathology; 2011 Feb; 43(2):143-8. PubMed ID: 21233676
[TBL] [Abstract][Full Text] [Related]
19. Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer.
Das S; Roth CP; Wasson LM; Vishwanatha JK
Prostate; 2007 Oct; 67(14):1550-64. PubMed ID: 17705178
[TBL] [Abstract][Full Text] [Related]
20. The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis.
Antunes AA; Leite KR; Sousa-Canavez JM; Camara-Lopes LH; Srougi M
J Urol; 2009 Feb; 181(2):594-600. PubMed ID: 19084862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
